Simon J Harrison

558 CTX130 allogeneic CRISPR-Cas9–engineered chimeric antigen receptor (CAR) T cells in patients with advanced clear cell renal cell carcinoma: Results from the phase 1 COBALT-RCC study

N. Agarwal, M. Hurwitz, B. Tran, 2022, Regular and Young Investigator Award Abstracts.